Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of 1.03 is 202% above its 5-year average of -1.01, around the middle of its 5-year range (-2.65–4.47).
14.88% below its 12-month average of 1.21.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 2.47.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 36 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T17:33:44.639Z. Historical observations retain their original dates. Historical series through 2026-10-05.
EARNINGS PER SHARE (EPS)
1.03
EARNINGS PER SHARE (EPS) AVG TTM
1.21
EARNINGS PER SHARE (EPS) AVG 3Y
-0.37
EARNINGS PER SHARE (EPS) AVG 5Y
-1.01
EARNINGS PER SHARE (EPS) AVG 10Y
-1.92
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-14.88%
CURRENT VS 3Y AVG
+376.51%
CURRENT VS 5Y AVG
+201.98%
CURRENT VS 10Y AVG
+153.67%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Protagonist Therapeutics, Inc.
Market Cap
$8.79B
Earnings Per Share (EPS)
1.03
TTM Avg
1.21
3Y Avg
-0.37
5Y Avg
-1.01
Market Cap
$8.69B
Earnings Per Share (EPS)
-2.24
TTM Avg
-2.51
3Y Avg
-2.15
5Y Avg
-1.80
Market Cap
$8.96B
Earnings Per Share (EPS)
-3.75
TTM Avg
-4.83
3Y Avg
-4.88
5Y Avg
-4.31
Market Cap
$8.98B
Earnings Per Share (EPS)
N/A
TTM Avg
0.30
3Y Avg
1.38
5Y Avg
1.40
Market Cap
$8.57B
Earnings Per Share (EPS)
-3.25
TTM Avg
-3.33
3Y Avg
-3.02
5Y Avg
-2.52
Market Cap
$8.41B
Earnings Per Share (EPS)
1.40
TTM Avg
-0.79
3Y Avg
-1.41
5Y Avg
-1.76
Market Cap
$9.28B
Earnings Per Share (EPS)
N/A
TTM Avg
0.30
3Y Avg
1.38
5Y Avg
1.40
Market Cap
$9.41B
Earnings Per Share (EPS)
-7.64
TTM Avg
-4.71
3Y Avg
-4.25
5Y Avg
-3.65
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Protagonist Therapeutics, Inc. (PTGX) | $8.79B | 1.03 | 1.21 | -0.37 | -1.01 |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.69B | -2.24 | -2.51 | -2.15 | -1.80 |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.96B | -3.75 | -4.83 | -4.88 | -4.31 |
| Bruker Corporation (BRKRP)vs › | $8.98B | N/A | 0.30 | 1.38 | 1.40 |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.57B | -3.25 | -3.33 | -3.02 | -2.52 |
| Oscar Health, Inc. (OSCR)vs › | $8.41B | 1.40 | -0.79 | -1.41 | -1.76 |
| Bruker Corporation (BRKR)vs › | $9.28B | N/A | 0.30 | 1.38 | 1.40 |
| Insulet Corp. (PODD)vs › | $9.33B | 5.35 | 4.74 | 3.13 | 2.14 |
| Vaxcyte, Inc. (PCVX)vs › | $9.41B | -7.64 | -4.71 | -4.25 | -3.65 |
| Krystal Biotech, Inc. (KRYS)vs › | $9.52B | 7.98 | 5.10 | 1.28 | 0.05 |
Trailing EPS (TTM)
$1.03
Forward EPS (Est.)
$4.67
P/E Ratio
132.2
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -2.05 |
| 2024-12-31 | 4.47 |
| 2023-12-31 | -1.39 |
| 2022-12-31 | -2.52 |
| 2021-12-31 | -2.65 |
| 2020-12-31 | -1.92 |
| 2019-12-31 | -2.98 |
| 2018-12-31 | -1.74 |
| 2017-12-31 | -2.09 |
| 2016-12-31 | -5.72 |
| 2015-12-31 | -2.52 |
| 2014-12-31 | -1.88 |
